MDS Virtual Congress 2021 » Parkinson’s Disease: Pharmacology and Therapy

A French national multicentric prospective study of the 1-year impact of STN-DBS on speech in Parkinson’s disease: profile of progression and prognostic factors.

T. Ollivier, S. Pinto, R. Viard, G. Kuchcinski, G. Touzet, L. Defebvre, D. Devos, C. Moreau (Lille, France)

ABBV-0805, a novel α-synuclein oligomer selective antibody, prolonged lifespan and prevented accumulation of α-synuclein pathology in mouse models of Parkinson’s disease

J. Fälting, F. Eriksson, J. Sigvardson, M. Johannesson, A. Kasrayan, M. Jones-Kostalla, P. Appelkvist, L. Söderberg, M. Blom, A. Rachalski, K. Nordenankar, O. Zachrisson, E. Amandius, G. Osswald, M. Moge, M. Ingelsson, J. Bergström, L. Lannfelt, C. Möller, M. Giorgetti, E. Nordström (Stockholm, Sweden)

Adherence to medication among Serbian Parkinson’s disease patients: a cross-sectional study

A. Milovanović, B. Radojević, NT. Dragašević-Mišković, M. Svetel, I. Petrović, A. Tomić-Pešić, M. Savić, D. Stanisavljević, VS. Kostić (Belgrade, Serbia)

Analysis of Amantadine formulations for OFF and Dyskinesia in Parkinson Disease

W. Oertel, R. Pahwa, R. Hauser, M. Sale, G. Went (Marburg, Germany)

Apomorphine infusion before subthalamic deep brain stimulation. A prospective comparative study in the same 20 patients.

G. Fernández-Pajarín, A. Sesar, B. Ares, I. Jimenez-Martín, M. Gelabert-González, E. Arán-Echabe, JL. Relova, A. Castro (Santiago de Compostela, Spain)

Assessment of Fluctuating Parkinson’s Disease with Sensor-Based Home Monitoring-Feasibility Results

T. Fay-Karmon, N. Galor, B. Heimler, R. Bartsch, A. Zilka, V. Livneh, M. Plotnik, S. Hassin-Baer (Ramat Gan, Israel)

Associations between Exercise Classes and Self-Reported Exercise by People with Parkinson’s Disease at Parkinson’s Foundation Centers of Excellence

E. Nettnin, S. Burrows, D. Simon, S. Wu, G. Miao, M. Rafferty (Chicago, USA)

Beta-antagonists and risk of Parkinson’s disease: Meta-analysis of real-world evidence studies

A. Singh, S. Hussain, B. Antony (Hobart, Australia)

Causes of deaths in patients with Parkinson’s disease in the era before the use of modern drug therapy and at the present time

S. Shtaimets (Omsk, Russian Federation)

CHAPERONIC PROPENSITIES OF AFRICAN WALNUT AS A THERAPEUTIC TARGET IN MANGANESE-INDUCED PARKINSON-LIKE NEUROPATHOLOGY IN WISTAR RATS

O. Tokunbo, B. Enaibe, T. Abayomi (Osogbo, Nigeria)

Classification of Advanced Parkinson’s Disease in OBSERVE-PD Patients Based on the MANAGE-PD Screening Tool

A. Fasano, V. Fung, K. Seppi, Z. Pirtosek, L. Bergmann, A. Alobaidi, K. Onuk (Toronto, Canada)

CLE-600: Treating nocturnal and early morning OFF symptomology in Parkinson’s disease with the OLAR® platform

E. Berkovich (Petch-Tikva, Israel)

Combined Plantar Stimulations Using a Novel Parkinson Shoe benefit Parkinson’s Disease Patients with Unresponsive Freezing of Gait

W. Phuenpathom, P. Panyakaew, S. Fungtammasan, P. Vateekul, R. Bhidayasiri (Bangkok, Thailand)

Community-Based Multidisciplinary Program for People with Parkinson Disease: A 2-year comparison

S. Parveen, T. Passmore, B. Brickell, S. Jackson (Stillwater, USA)

Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Patients With Advanced Parkinson’s Disease

M. Soileau, F. Pagan, A. Fasano, R. Rodriguez, N. Gupta, A. Xi, M. Kambhampati, A. Murunga, C. Teigland, P. Kandukuri, Y. Jalundhwala, O. Ladhani, M. Siddiqui (Georgetown, USA)

Comparison and analysis of pupillometer parameters between patients with drug naive Parkinson’s disease and controls

S. You, J. Yoo (Daegu, Republic of Korea)

Comparison of Antiparkinsonian Medication Initiation and Levodopa-Equivalent Daily Dose Across PPMI, STEADY-PD III, and SURE-PD3

J. Chan, N. Hanan, J. Lowell, M. Kostrzebski, D. Penz, C. Tarolli, T. Mestre, A. Lutz, C. Lungu, C. Coffey, D. Oakes, M. Schwarzschild, T. Simuni, E. Macklin (Boston, USA)

Compensation strategies for gait impairment in Parkinson’s disease: a survey among 4,324 patients

A. Tosserams, L. Wit, I. Sturkenboom, M. Nijkrake, B. Bloem, J. Nonnekes (Nijmegen, Netherlands)

Determination of the motor status after the implementation Levodopa-carbidopa intestinal gel in patients with advanced Parkinson’s disease using a Machine learning Algorithm

E. Efthymiopoulou, A. Antonoglou, B. Loupo, A. Bougea (Athens, Greece)

Directional steering in subthalamic deep brain stimulation for Parkinson’s disease: the Berlin experience

V. Heinz, A. Marcelino, GH. Schneider, A. Kühn (Berlin, Germany)

DOPAMINERGIC AND NON-DOPAMINERGIC TREATMENT AFTER DEEP BRAIN STIMULATION (DBS) IN PARKINSON DISEASE (PD). IMPORTANCE OF NON MOTOR SYMPTOMS (NMS)

T. Muñoz Ruiz, L. García Trujillo, G. Pons Pons, L. Romero Moreno, M. Troya Castilla, V. Fernández Sánchez, P. Serrano Castro (Málaga, Spain)

Early versus later levodopa and onset of motor fluctuations in PD: Observations from the Parkinson’s Outcomes Project

S. Chiu, A. Ramirez-Zamora, B. Patel, S. Wu, H. Gao, O. Nguyen, I. Malaty (Gainesville, USA)

Effect of H. pylori Infection on L-DOPA Pharmacokinetics in Patients with Parkinson’s disease.

S. Oda, Y. Saitoh, J. Takei, S. Watanabe, Y. Mukai, Y. Takahashi (Kodaira, Japan)

Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson’s Disease

M. Beke, P. Mackie, C. Rusch, E. Klann, A. Gurrala, S. Chua, E. Ince, L. Almeida, A. Ramirez-Zamora (Gainesville, USA)

Effect of oxytocin on response inhibition in Parkinson´s disease: a pilot study

F. Carbone, P. Ellmerer, S. Spielberger, M. Peball, V. Sidoroff, M. Ritter, K. Seppi, W. Poewe, A. Djamshidian (Innsbruck, Austria)

Effect of simultaneous mGlu2 positive allosteric modulation and orthosteric stimulation combined with 5-HT2A antagonism on psychosis-like behaviours, dyskinesia and parkinsonism in the MPTP-lesioned marmoset

S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

Effect of the GlyT1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset

I. Frouni, SG. Nuara, D. Bédard, A. Hamadjida, JC. Gourdon, P. Huot (Montreal, Canada)

Effect of the mGlu2/3 orthosteric agonist LY-404,039 on abnormal involuntary movements and parkinsonism in the 6-OHDA-lesioned rat

W. Kang, I. Frouni, C. Kwan, L. Desbiens, D. Bédard, A. Hamadjida, P. Huot (Montreal, Canada)

Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of entacapone: findings from the real-world OPTIPARK study

W. Jost, H. Reichmann, A. Lees, D. Marinho, D. Magalhães, J. Rocha, P. Soares-da-Silva (Wolfach, Germany)

Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of monoamine-oxidase-B inhibitors (MAO-B) and dopamine agonists (DA): findings from the real-world OPTIPARK study

H. Reichmann, T. Warnecke, A. Lees, D. Martins, D. Magalhães, J. Rocha, P. Soares-da-Silva (Dresden, Germany)

Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of safinamide: findings from the real-world OPTIPARK study

N. Pavese, A. Lees, H. Reichmann, D. Martins, D. Magalhães, J. Rocha, P. Soares-da-Silva (Newcastle Upon Tyne, United Kingdom)

Effects of low frequency repetitive transcranial stimulation over right dorsolateral prefrontal region on clinical symptoms and sleep structure of Parkinson’s disease Abstract

WU. Jing, C. Jing, Z. Sheng, LIU. Feng (Suzhou, China)

Effects of Once-Daily Opicapone 50 mg on the Pharmacokinetics of Levodopa Administered as Carbidopa/Levodopa Extended-Release Capsules: An Open-Label Phase 1 Study

G. Loewen, A. Vijan, K. Olson, T. O’Reilly, G. Liang, O. Klepitskaya (San Diego, USA)

Efficacy and safety of Levodopa-Carbidopa Intestinal Gel in the treatment of Parkinson’s Disease

E. Londero, A P. Dos Santos, R. Braga, R. de Barros, L. Dos Reis, G. Freire (Salvador, Brazil)

Electroconvulsive therapy for refractory psychiatric symptoms in GBA-related Parkinson disease patient

JY. Yun, EH. Lee (Seoul, Republic of Korea)

Evaluating a Novel Home-Based Care Pathway for People with Parkinson’s Disease

E. King, J. Abraham, E. Edwards, T. Gorst, M. Holley, J. Inches, T. North, J. Rideout, S. Whipps, C. Carroll (Plymouth, United Kingdom)

Evaluation of a double-target therapeutic in preclinical models of Parkinson’s disease

FJ. Sanz, C. Solana-Manrique, E. Masià, MJ. Vicent, N. Paricio (Burjassot, Spain)

Exploring the Potential Anti-dementia Roles of Selected Herbal Anti-inflammatory Remedies in Parkinson’s Disease: Hopes and Challenges

SA. Atunwa (Ilorin, Nigeria)

Findings from a Community-based LOUD Crowd® Program for People with Parkinson Disease

S. Parveen, A. Mandaville (Stillwater, USA)

Global access to Parkinson’s disease treatment

JLY. Cheong, ZHK. Goh, C. Marras, C. Tanner, M. Kasten, A. Korczyn, L. Chahine, R. Lo, A. Noyce (London, United Kingdom)

Gut bacterial tyrosine decarboxylase as a predictive biomarker to identify Parkinson’s disease patients with motor fluctuations requiring frequent levodopa administration

S. van Kessel, L. Verhagen Metman, G. Sanzo, P. Mcnamara, A. Keshavarzian, S. El Aidy (Groningen, Netherlands)

Impact on Dyskinesia in Advanced Parkinson’s Disease Patients Treated with LCIG: Analysis from the COSMOS Study

A. Fasano, C. Spanaki, T. Gurevich, M. Simu, L. Bergmann, J. Parra, P. Sanchez Vega, O. Sanchez-Soliño, N. Kovács (Toronto, Canada)

Improved Excessive Daytime Sleepiness with Selegiline in patients with Parkinson’s Disease: An Open Trial

JR. Zhang, JP. Chen, J. Li, J. Li, CJ. Mao, CF. Liu (Suzhou, China)

Indirect Treatment Comparison of Adjunctive Treatments for Patients with Parkinson’s Disease Experiencing Motor Complications

D. Kremens, W. Oertel, R. Pahwa, R. Hauser, C. Lecureuil, R. Johnson, G. Went (Philadelphia, USA)

Influence of demographic characteristics on the effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations: findings from the real-world OPTIPARK study

B. Mohamed, A. Lees, H. Reichmann, D. Martins, D. Magalhães, J. Rocha, P. Soares-da-Silva (Cardiff, United Kingdom)

Influence of Dopamine Transporter Gene Polymorphism on Wearing Off

CE. Mantese, V. Altmann, A. Schumacher-Schuh, M. Hutz, CRM. Rieder (Porto Alegre, Brazil)

Influence of onset of motor fluctuations on the effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations: findings from the real-world OPTIPARK study

W. Jost, H. Reichmann, A. Lees, D. Marinho, D. Magalhães, J. Rocha, P. Soares-da-Silva (Wolfach, Germany)

Inhibition of GluN2D-containing NMDA receptors alleviates the loss of dopaminergic neurons and behavioral deficits in 6-OHDA-induced model of Parkinson’s disease

JB. Zhang, C. Ren, KJ. He, F. Wang, CF. Liu (Suzhou, China)

IS THE HYPOXIA EXPOSURE BENEFICIAL FOR PEOPLE WITH PARKINSON’S DISEASE? A SCOPE REVIEW

C. Kalva-Filho, M. Kuroda, E. Costa, J. Corradini, F. Barbieri (Bauru, Brazil)

Istradefylline/L-DOPA combination therapy for Parkinson’s disease and blood markers of glycolytic energy homeostasis

NAO. Kanzato, KO. Nakachi, MA. Hayashi, F. Kinjyo, W. Mizuta, SA. Mochizuki (Haebaru-Cho, Okinawa, Japan)

Levodopa responsive gait dynamics in ON- and OFF-state freezing of gait in Parkinson’s disease

T. Virmani, L. Pillai, A. Glover, R. Landes (Little Rock, USA)

Levodopa-Carbidopa Intestinal Gel Therapy for Advanced Parkinson’s Disease: A Single Center ‘Real World’ Study of Patients with and without DBS

P. Dole, S. Green, M. Wiggins, J. Joseph, M. Gaspari, M. Siddiqui (Winston-Salem, USA)

Levodopa/carbidopa intestinal gel (LCIG) reduces fluctuations and shortens time to on without troublesome dyskinesia in advanced Parkinson’s Disease: Post-hoc analyses of 54-week LCIG-monotherapy trial

R. Pahwa, J. Aldred, A. Merola, N. Gupta, E. Terasawa, V. Garcia-Horton, P. Kandukuri, Y. Jalundhwala, Y. Bao, O. Ladhani, S. Isaacson (Kansas City, USA)

Limitations of conventional dopaminergic medication in advanced Parkinson’s disease: results from 127 patients treated with Levodopa Carbidopa Intestinal Gel

J. Szász, V. Constantin, K. Orban-Kiss, L. Bancu, D. Georgescu, J. Szederjesi, M. Ciorba, A. Racz, I. Mihaly, K. Kelemen, S. Szatmari (Targu Mures, Romania)

Local Field Potentials (LFP) used to guide treatment of biphasic dyskinesias in a patient with Parkinson’s Disease (PD)

O. Vaou, C. Harrington, S. Stanslaski, R. Cosgrove, A. Depold Hohler (Brighton, USA)

Long-term real-world effectiveness of carbidopa/levodopa enteral suspension after 36 months of treatment initiation: Final results from PROviDE study

R. Pahwa, S. Isaacson, R. Dorsey, D. Cella, B. Bluett, S. Thakkar, P. Kandukuri, N. Gupta, Y. Jalundhwala, Y. Bao, I. Pan, O. Ladhani, J. Aldred (Kansas City, USA)

LY-487,379 alleviates parkinsonism when administered as monotherapy in the MPTP-lesioned marmoset

I. Frouni, C. Kwan, S. Nuara, S. Belliveau, A. Hamadjida, W. Kang, D. Bédard, J. Gourdon, P. Huot (Montreal, Canada)

LY-487,379 enhances the anti-parkinsonian action of a low dose of L-DOPA in the MPTP-lesioned marmoset

C. Kwan, I. Frouni, S. Nuara, S. Belliveau, A. Hamadjida, W. Kang, D. Bédard, J. Gourdon, P. Huot (Montreal, Canada)

Neuroprotective Epigenetic and DNA-Repair Molecular Mechanisms of Acetyl-L-Carnitine and Astaxanthin Against 6-OHDA Induced Parkinsonism in Aged Rats

S. Kumar, P. Kumar, A. Williams, M. Anifowose, K. Ponnusamy (Puducherry, India)

Opicapone Analysis of Health Economic Costs in Clinical Practice in Parkinson’s Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study

A. Lees, H. Reichmann, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)

Opicapone in clinical practice in Parkinson’s disease patients with motor fluctuations and complications of therapy at baseline: findings from the OPTIPARK study

H. Reichmann, A. Lees, M. Fonseca, D. Magalhães, J. Rocha, P. Soares-da-Silva (Dresden, Germany)

Opicapone in Clinical Practice in Parkinson’s Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study

A. Lees, H. Reichmann, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)

Opicapone in Parkinson’s Disease German Patients with Motor Fluctuations: Findings from the OPTIPARK Study

H. Reichmann, A. Lees, D. Magalhães, J. Rocha, P. Soares-da-Silva (Dresden, Germany)

Opicapone in Parkinson’s disease patients with early/simple motor fluctuations: real-world Spanish data

M. Mata Alvarez-Santullano, C. Borrue Fernández, CM. Labandeira Guerra, T. Muñoz Ruiz, J. Abril Jamarillo, V. Gómez Mayordomo, PE. Bermejo Velasco (San Sebastián Reyes, Spain)

OPTIMIPARK Questionnaire:a tool to optimize treatment in Parkinson´s disease.

J. Máñez-Miró, F. Vivancos-Matellano, L. Vela-Desojo, R. Martinez-Fernandez, F. Alonso-Frech, N. Lopez-Aristegui, E. Balaguer-Martínez, J. Martinez-Castrillo, L. Lopez-Manzanares, P. Martínez-Martín (Madrid, Spain)

Parkinson’s Disease Medication Safety in the Inpatient Cohort of a Tertiary Centre

A. Redmond, G. Richard, M. Penugonda, D. Bradley (Dublin 8, Ireland)

Pilot study of Phenotype of Antisense-Oligonucleotide-(ASO)-knockdown of Cerebral-Dopamine-Neurotrophic-Factor (CDNF) as Parkinson Disease model : implications for PD and related Dementia Therapeutics

SS. Chiu, K. Terpstra, RK. Mishra (London, Canada)

Potential drug-drug interactions in hospitalized patients with Parkinson’s disease from tertiary center in Serbia

D. Aleksic, S. Stefanovic, M. Milosavljevic, J. Milosavljevic, S. Jankovic (Kragujevac, Serbia)

Predictive factors of LCIG infusion therapy adherence – a single-center study of 103 consecutive LCIG patients

V. Viljaharju, T. Mertsalmi, KAM. Pauls, M. Koivu, J. Eerola-Rautio, M. Udd, E. Pekkonen (Helsinki, Finland)

Problems faced by Parkinson’s disease patients during COVID-19 pandemic compulsory lockdown and its management with the help of Telemedicine in a North Indian cohort

K. Shukla, N. Sawal (Chandigarh, India)

Quantitative systems pharmacology modelling of Parkinson’s disease to compare anti-α-synuclein therapeutics

S. Bakshi, PH. Vander Graaf (Breda, Netherlands)

Real-world characteristics of advanced Parkinson’s disease patients initiating carbidopa/levodopa enteral suspension

M. Soileau, I. Malaty, J. Aldred, A. Merola, R. Rodriguez, N. Gupta, I. Sultan, P. Kandukuri, Y. Jalundhwala, O. Ladhani, I. Pan, R. Pahwa (Georgetown, USA)

Registry Analysis (In Progress) to Evaluate Clinical Outcomes and Disease Burden of Advanced PD in Patients With Motor Fluctuations and Dyskinesia Managed With Oral Dopaminergic Therapies Versus Device-Aided Therapies

W. Hu, O. Ladhani, P. Kukreja, A. Ramirez-Zamora (Gainesville, USA)

Safety and Tolerability of a Ketone Supplement in Parkinson’s Disease

M. Beke, P. Mackie, E. Klann, C. Rusch, A. Gurrala, S. Chua, E. Ince, L. Almeida, A. Ramirez-Zamora (Gainesville, USA)

Safety, tolerability and CNS effects after single and multiple doses of β-agonists in healthy volunteers and patients with Parkinson’s disease

P. Eijsvogel, S. Prins, L. Moss, L. Borghans, B. van Kraaij, E. van Brummelen, E. Klaassen, R. Martin, E. Bautista, A. Ford, GJ. Groeneveld, G. Vargas (Leiden, Netherlands)

Safinamide Improves Mood in Parkinson´s Disease. Results from the SAFINONMOTOR Study.

C. Labandeira, MG. Alonso Losada, R. Yáñez Baña, I. Cimas Hernando, I. Cabo López, JM. Paz González, MJ. González Palmás, C. Martínez Miró, D. Santos García (Vigo, Spain)

Safinamide Improves Pain in Parkinson´s Disease. Results from the SAFINONMOTOR Study.

R. Yáñez, C. Labandeira, M. Cimas Hernando, I. Cabo, J. Paz González, M. Alonso Losada, M. González Palmás, C. Martínez, D. Santos García (Ourense, Spain)

Safinamide Improves Sleep and Daytime Sleepiness in Parkinson´s Disease. Results from the SAFINONMOTOR Study

I. Cabo López, C. Labandeira Guerra, R. Yáñez Baña, MI. Cimas Hernando, JM. Paz González, MG. Alonso Losada, MJ. González Palmás, C. Martínez Miró, D. Santos García (Pontevedra, Spain)

SB-0107, a drug repurposing opportunity identified through machine learning, shows the potential to treat Parkinson’s disease motor disability and levodopa-induced dyskinesia in rat and primate models

A. Bordbar, K. Merchant, D. Weiner, M. Hill, J. Brotchie, T. Johnston, I. Famili (San Diego, USA)

STATINS IN PARKINSON’S DISEASE: INFLUENCE ON MOTOR PROGRESSION

G. Palermo, S. Giannoni, M. Giuntini, E. Belli, D. Frosini, G. Siciliano, R. Ceravolo (Pisa, Italy)

Survey-Based study of marijuana used in Parkinson’s Disease patients

R. Healy, J. Paulson, A. Deb, K. Smith (Worcester, USA)

The early post-transplant period in Parkinson’s disease: the low intravenous dose effect.

V. Chyzhyk, V. Ponomarev, N. Aleinikava, A. Boika, M. Zafranskaya, D. Nizheharodava (Minsk, Belarus)

The effect of medical xenon on patients with advanced stages of the Parkinson’s disease with motor fluctuations

R. Bogdanov, E. Vasilchenko, A. Dobrovolsky, P. Ratmanova, D. Napalkov, V. Bogin (Moscow, Russian Federation)

THE EFFECT OF VITAMIN D IN PARKINSON’S DISEASE

E. Göger, G. Yüksel, G. Gürsoy (İstanbul, Turkey)

The effectiveness of home modification on gait and falling episode in Parkinson’s disease (PD) patients.

J. Sringean, S. Phumphid, N. Kantachadvanich, R. Bhidayasiri (Bangkok, Thailand)

The EON (Elderly patients on ONgentys) study in Parkinson’s disease: design and rationale of a prospective non-interventional trial

V. Dostal, K. Chaudhuri, P. Odin, M. Kurtis, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Norwich, United Kingdom)

The gender gap in Parkinson’s disease before and after Subthalamic Nucleus Deep Brain Stimulation surgery: preliminary results of a retrospective study.

A. Trinchillo, F. Vitulli, T. Somma, F. Esposito (Naples, Italy)

The GlyT1 inhibitor bitopertin reduces in the 6-OHDA-lesioned rat model of Parkinson’s disease

I. Frouni, W. Kang, C. Kwan, D. Bedard, A. Hamadjida, P. Huot (Montreal, Canada)

The mitochondrial targeted drug SBT-272 attenuates dopaminergic neuron loss, alpha-synuclein burden and neuroinflammation in a mouse model of Parkinson’s Disease

S. Bido, J. Kūka, M. Makrecka-Kuka, G. Zheng, D. Keefe, V. Broccoli (Milan, Italy)

The PD-1102 trial in advanced Parkinson’s disease: safety and clinical outcomes from a 3-year phase 1b study of AADC gene therapy administered via a posterior approach

S. Factor, R. Gross, A. van Laar, C. Christine, P. Larson, S. Kostyk, R. Lonser, E. Fine, O. Kwhaja, C. Li, A. Meier, G. Liang, E. Roberts, R. Richardson (Atlanta, USA)

The potential of GBA1 knock-out medaka as a model animal in the search for therapeutic compounds for GBA1-related α-synucleinopathy

E. Nakanishi, M. Sawamura, Y. Taruno, N. Uemura, H. Yamakado, R. Takahashi (Kyoto, Japan)

The responsiveness of arm swing to dopaminergic medication in Parkinson’s disease depends on task complexity

E. Warmerdam, R. Romijnders, C. Hansen, M. Elshehabi, M. Zimmermann, F. Metzger, A. von Thaler, D. Berg, G. Schmidt, W. Maetzler (Kiel, Germany)

The Transcriptome from Multiple Regions of the MPTP-induced Parkinson’s disease Mouse Brain after exercise

T. Tong, Z. Zhang, Z. Zhang, H. Hu, L. Li, J. Jin (Shanghai, China)

Validation of a real- time monitoring system to detect motor symptoms in patients with Parkinson´s disease treated with Levodopa Carbidopa Intestinal Gel

A. Bougea, M. Palkopoulou, S. Pantinaki, A. Antonoglou, E. Efthymiopoulou (Athens, Greece)

Validation of the Neuroprotective Potential of SLP-2 against alpha-synuclein neuropathology in a Mouse Model of Parkinson’s Disease

C. Bolduc, M. Lorente Picón, S. Laouafa, J. Soliz, I. Pichler, M. Lévesque (Québec, Canada)

VMAT2 OVEREXPRESSION REDUCES INTRACELLULAR NEUROMELANIN LEVELS AND ATTENUATES PARKINSON-LIKE PATHOLOGY IN NEUROMELANIN-PRODUCING PARKINSONIAN RATS

J. Compte, M. González, A. Nicolau, T. Cuadros, J. Romero, A. Parent, A. Laguna, M. Vila (Barcelona, Spain)

Wearable sensor motor outcomes across patients with Parkinson’s disease from Asian, Black, and Caucasian ethnicity in the United Kingdom

D. van Wamelen, L. Batzu, A. Podlewska, D. Trivedi, K. Ray Chaudhuri (London, United Kingdom)

α-synuclein expression is not mediated by β2-adrenoreceptor modulation in human dopaminergic cells

M. Langmyhr, IH. Flønes, CC. Cappelletti, C. Tzoulis, M. Toft (Oslo, Norway)